Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Recursion Pharmaceuticals Inc (RXRX) vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. (ZTO) Price & Performance

Recursion Pharmaceuticals IncTrade
ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.Trade

Price performance (Past 24H)

Key statistics

Recursion Pharmaceuticals Inc vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. — how do they compare? Recursion Pharmaceuticals Inc trades at $4.41 (market cap $2.14B), while ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. trades at $20.12 (market cap $14.70B). The key difference: ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. is far larger — about 6.9× Recursion Pharmaceuticals Inc's market cap, and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. pays a 3.47% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

RXRXZTO
Market Cap
$2.14B$14.70B
Volume
30,789,5351,484,646
Sector
HealthIndustrials
52-Week High
$6.79$25.88
52-Week Low
$2.84$18.50
Typical Hold Time
23 Days—
Enterprise Value
$1.66B$13.32B
Dividend Yield
—3.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Recursion Pharmaceuticals Inc

RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.

The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.

ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RXRX
86% Buy14% Sell
Avg holding period · 23 Days
ZTO

No sentiment data available yet.

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX →

About ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.

ZTO Express provides domestic and international express delivery services in China. Its network-partner model combines ZTO's sorting and trunk transportation with partners' pickup and last-mile delivery.

Read more on ZTO →